Cantel Medical Corp. (NYSE:CMD) Sees Large Drop in Short Interest

Share on StockTwits

Cantel Medical Corp. (NYSE:CMD) saw a significant decrease in short interest during the month of September. As of September 15th, there was short interest totalling 3,030,000 shares, a decrease of 9.6% from the August 31st total of 3,350,000 shares. Currently, 8.5% of the company’s shares are sold short. Based on an average trading volume of 474,800 shares, the days-to-cover ratio is currently 6.4 days.

NYSE:CMD traded down $1.19 on Friday, hitting $42.85. 419,440 shares of the stock were exchanged, compared to its average volume of 443,285. The stock has a market cap of $1.81 billion, a PE ratio of 26.53, a PEG ratio of 10.53 and a beta of 1.39. The company has a current ratio of 3.60, a quick ratio of 2.66 and a debt-to-equity ratio of 1.44. The stock has a fifty day moving average of $49.76 and a 200-day moving average of $42.28. Cantel Medical has a fifty-two week low of $20.81 and a fifty-two week high of $79.50.

Separately, Bank of America started coverage on Cantel Medical in a research note on Wednesday, August 19th. They set an “underperform” rating and a $51.00 price target for the company.

Cantel Medical Company Profile

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services.

Featured Article: What is a Reverse Stock Split?

Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply